Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

National Cancer Institute of Canada Clinical Trials Group MA.17, Paul E Goss, James N Ingle, Silvana Martino, Nicholas J Robert, Hyman B Muss, Martine J Piccart, Monica Castiglione, Dongsheng Tu, Lois E Shepherd, Kathleen I Pritchard, Robert B Livingston, Nancy E Davidson, Larry Norton, Edith A Perez, Jeffrey S Abrams, David A Cameron, Michael J Palmer, Joseph L Pater

Research output: Contribution to journalArticlepeer-review

Abstract

Controversy exists regarding estrogen (ER) and progesterone (PgR) receptor expression on efficacy of adjuvant endocrine therapy. In the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, the benefit of anastrozole over tamoxifen was substantially greater in ER+/PgR-than ER+/PgR+ tumors. In BIG 1-98 (Breast International Group), the benefits of letrozole over tamoxifen were the same in ER+ tumors irrespective of PgR. MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status.
Original languageEnglish
Pages (from-to)2006-11
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number15
DOIs
Publication statusPublished - 20 May 2007

Keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Canada
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Humans
  • Middle Aged
  • Nitriles
  • Placebos
  • Postmenopause
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Retrospective Studies
  • Survival Rate
  • Tamoxifen
  • Treatment Outcome
  • Triazoles

Fingerprint

Dive into the research topics of 'Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17'. Together they form a unique fingerprint.

Cite this